Stock Code: 000028/200028 Notice No.: 2022-23
Short Form of the Stock: SinopharmAccord /Accord B
China NationalAccord Medicines Corporation Ltd.
The First Quarterly Report for 2022
The Company and whole members of the BOD guarantee that the information disclosed is true,
accurate and complete, and there are no any fictitious records, misleading statements or important
omissions.
Important content reminder:
1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements, misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ
(Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic, accurate
and complete.
3. Whether the First Quarterly Report has been audited or not
□Yes √No
I. Main financial data
(i) Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□Yes√ No
Current Period Same period of last year Changes of this period over
same period of last year
Operating income (RMB) 17,150,856,946.54 16,049,966,325.75 6.86%
Net profit attributable to shareholders of 252,361,872.69 328,800,560.24 -23.25%
the listed company (RMB)
Net profit attributable to shareholders of
the listed company after deducting 242,244,636.06 321,593,612.98 -24.67%
non-recurring gains and losses (RMB)
Net cash flow arising from operating -217,452,223.38 -306,748,999.24 29.11%
activities (RMB)
Basic earnings per share (RMB/Share) 0.59 0.77 -23.38%
Diluted earnings per share (RMB/Share) 0.59 0.77 -23.38%
Weighted average ROE 1.68% 2.33% 0.65 percentage points
down
Changes of this period-end
End of this period End of last period over same period-end of last
year
Total assets (RMB) 44,844,103,338.63 42,783,682,431.81 4.82%
Owners’equity attributable to shareholders 15,177,183,542.81 14,924,938,052.50 1.69%
of listed company (RMB)
Explanation on the business performance and financial status:
The Company achieved operation income of 17,151 million yuan for the first quarter of 2022, a year-on-year increase of 6.86%;
operation profit was 375 million yuan, 20.42% down from a year earlier; the net profit attributable to shareholder of listed company
was 252 million yuan, decrease of 23.25% on a year-on-year basis, the basic EPS decreased by 23.38% correspondingly and
weighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19, the performance from
affiliates declined and the investment earnings decreased accordingly. Meanwhile, the customer flow from retail segment drops due
to the epidemic, and the new stores operated in 2021 have a large initial investment, the benefits are not yet visible with shrinking
profit space.
The distribution segment has an operation income of 12,171 million yuan, a year-on-year growth of 7.45%; net profit was 210
million yuan, a year-on-year increase of 10.40%. the retail segment has 5,238 million yuan from the operation income, a year-on-year
increase of 5.11% and achieved a net profit of 32 million yuan, down 63.80% on a year-on-year basis.
(ii) Items of non-recurring gains and losses
√ Applicable □ Not applicable
Unit: RMB/CNY
Item Current amount Note
Gains/losses from the disposal of non-current asset (including the The gains on disposal of
785,738.83 right-to-use asses arising from
write-off that accrued for impairment of assets)
查看PDF原文
